<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712163</url>
  </required_header>
  <id_info>
    <org_study_id>NKT-101</org_study_id>
    <nct_id>NCT03712163</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, 2-Part, Single Ascending Dose and Multiple Dose Cohort Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergo Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergo Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center, double-blind, randomized, placebo-controlled, 2-part,
      single ascending dose and multiple dose cohort study of orally administered Norketotifen
      (NKT) in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single Ascending Dose: Three single ascending dose cohorts are planned. A total of 10
      subjects will be enrolled in each cohort and will be randomly assigned to receive a single
      oral dose of NKT (n=8) or a matching placebo (n=2). A Safety Review Team (SRT) will review
      all available safety data in a blinded manner following the completion of each cohort to
      determine the next dose level to be evaluated in the next cohort.

      Multiple Dose Cohort: A total of 10 subjects will be enrolled and will be randomly assigned
      to receive multiple oral doses of NKT (n=8) or a matching placebo (n=2) once daily for an
      adequate number of days to reach steady state (the number of days will be determined based on
      the half-life of NKT in Part A). The dose of NKT to be evaluated will be determined by the
      SRT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">March 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events following single doses</measure>
    <time_frame>Through Day 4</time_frame>
    <description>Including clinically significant and Grade 3 abnormalities in laboratory values, vital signs, ECGs, and physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
    <description>Including clinically significant and Grade 3 abnormalities in laboratory values, vital signs, ECGs, and physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) following single doses</measure>
    <time_frame>Through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) following single doses</measure>
    <time_frame>Through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) following single doses</measure>
    <time_frame>Through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2) following single doses</measure>
    <time_frame>Through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2) following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) following single doses</measure>
    <time_frame>Through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) following single doses</measure>
    <time_frame>Through Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) following multiple doses</measure>
    <time_frame>Through Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Norketotifen or Placebo (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norketotifen or Placebo (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norketotifen or Placebo (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norketotifen or Placebo (Multiple Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norketotifen Oral Capsule (Cohort 1)</intervention_name>
    <description>Single dose Norketotifen</description>
    <arm_group_label>Norketotifen or Placebo (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norketotifen Oral Capsule (Cohort 2)</intervention_name>
    <description>Single dose Norketotifen</description>
    <arm_group_label>Norketotifen or Placebo (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norketotifen Oral Capsule (Cohort 3)</intervention_name>
    <description>Single dose Norketotifen</description>
    <arm_group_label>Norketotifen or Placebo (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norketotifen Oral Capsule (Multiple Dose Cohort)</intervention_name>
    <description>Multiple dose Norketotifen</description>
    <arm_group_label>Norketotifen or Placebo (Multiple Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Norketotifen or Placebo (Cohort 1)</arm_group_label>
    <arm_group_label>Norketotifen or Placebo (Cohort 2)</arm_group_label>
    <arm_group_label>Norketotifen or Placebo (Cohort 3)</arm_group_label>
    <arm_group_label>Norketotifen or Placebo (Multiple Dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body mass index (BMI) of 18 to 30 kg/m^2

          -  Negative serum pregnancy test (females); females of childbearing potential and males
             must agree to use acceptable contraception

        Key Exclusion Criteria:

          -  Pregnant or lactating (females)

          -  Clinically significant past or current medical or surgical history

          -  Clinically significant illness or abnormality on physical examination, 12-lead ECG,
             laboratory values

          -  Participation in an investigational drug or device study within 30 days prior to
             Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Zamora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

